Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 8/20 | 0.66 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | NQO1 | P15559 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22863319 | 0.86 | NAALAD2 (0.63) | NAALAD2FTONR1H2TTRJAK2 | |
| SCHEMBL15744221 | 0.86 | FTO (0.64) | NAALAD2FTONR1H2TTRJAK2 | |
| SCHEMBL20729848 | 0.86 | FTO (0.66) | NAALAD2FTONR1H2TTRJAK2 | |
| SCHEMBL17956697 | 0.86 | FTO (0.69) | NAALAD2FTONR1H2TTRJAK2 | |
| SCHEMBL22314141 | 0.85 | FTO (0.63) | NAALAD2FTONR1H2TTRJAK2 | |
| SCHEMBL8893358 | 0.85 | NAALAD2 (0.62) | NAALAD2FTONR1H2TTRFOLH1 | |
| SCHEMBL29353892 | 0.85 | FTO (0.63) | NAALAD2FTONR1H2TTRFOLH1 | |
| SCHEMBL991216 | 0.85 | FTO (0.63) | NAALAD2FTONR1H2TTRFOLH1 | |
| SCHEMBL12754623 | 0.85 | FTO (0.65) | NAALAD2FTONR1H2TTRJAK2 | |
| SCHEMBL9293647 | 0.85 | FTO (0.64) | NAALAD2FTOTTRJAK2NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-RE47684-E1 | Cytoprotective agent | TMS CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| US-9078880-B2 | Cytoprotective agent | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20120135996-A1 | CYTOPROTECTIVE AGENT | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135996-A1 | CYTOPROTECTIVE AGENT | TXN2, TXNRD2, AIFM1 | NAALAD2 2639/4885FTO 4787/4885NR1H2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.